We are live on ! Find out more
ADIL icon

Adial Pharmaceuticals
ADIL

19 hedge funds and large institutions have $3.15M invested in Adial Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

429% more capital inflows, than outflows

Capital inflows: $1.28M | Capital outflows: $243K

2.03% more ownership

Funds ownership: 4.67% → 6.7% (+2%)

0% more funds holding

Funds holding: 19 → 19 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

Holders
19
Holders Change
–
Holders Change %
0%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$900K
2
State Street
State Street
Massachusetts
+$119K
3
Virtu Financial
Virtu Financial
New York
+$76.1K
4
GG
Golden Green
South Carolina
+$60.8K
5
Northern Trust
Northern Trust
Illinois
+$53.2K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$132K
2
Barclays
Barclays
United Kingdom
-$38K
3
BlackRock
BlackRock
New York
-$24.3K
4
Creative Planning
Creative Planning
Kansas
-$24K
5
UBS Group
UBS Group
Switzerland
-$11K

ADIL Hedge Fund Activity: Q2 2021 in Review

19 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2021, worth a combined $3.15M — up 61% from $1.95M a quarter earlier.

Fund positioning in ADIL was balanced in Q2 2021: 4 funds opened new positions, 4 closed out, 4 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, adding an estimated $900K. The largest seller was Citadel Advisors, cutting an estimated $132K.

  • 19 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2021, unchanged from Q1 2021.
  • Funds reported $3.15M of Adial Pharmaceuticals stock for Q2 2021, up 61% quarter-over-quarter.
  • 4 funds opened new Adial Pharmaceuticals positions in Q2 2021 and 4 closed out, a net change of 0 holders.
  • The largest Adial Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $900K added.
  • The largest Adial Pharmaceuticals seller in Q2 2021 was Citadel Advisors, an estimated $132K sold.

Based on aggregated 13F filings for Q2 2021.